Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine: A pilot study

被引：3

作者：

Adachi, Eisuke ^{[1
,2
]}

Ikeuchi, Kazuhiko ^{[1
]}

Koga, Michiko ^{[1
]}

Yotsuyanagi, Hiroshi ^{[1
]}

机构：

[1] Univ Tokyo, IMSUT Hosp Inst Med Sci, Dept Infect Dis & Appl Immunol, Tokyo, Japan

[2] Univ Tokyo, IMSUT Hosp Inst Med Sci, Dept Infect Dis & Appl Immunol, 4 6 1 Shirokanedai Minato ku, Tokyo 1088639, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2023年 / 29卷 / 01期

关键词：

Cabotegravir plus rilpivirine; Long-acting drug; HIV; Stigma A; ntiretroviral therapy;

D O I：

10.1016/j.jiac.2022.09.008

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Long-acting therapy of cabotegravir and rilpivirine is expected to free people from the negative emotions of living with HIV associated with taking drugs, but problems such as increased number of hospital visits, lack of anti-HBV activity, and limited convenience in people with concomitant drugs have been noted. In this single -center, prospective, cross-sectional study, we investigated background factors of people living with HIV in Japan who chose cabotegravir plus rilpivirine. Forty-seven percent (36 of 76) of individuals chose this regimen, but many people living with HIV who visited the hospital once every 3 months or needed concomitant medi-cations due to complications chose this regimen and there were no significant differences in background factors that could affect convenience between the groups of those who switched and those who did not.

引用

页码：109 / 111

页数：3

共 8 条

[1] Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection [J].

Dandachi, Dima ;

Dang, Bich N. ;

Lucari, Brandon ;

Swindells, Susan ;

Giordano, Thomas P. .

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2021, 33 (06) :801-809

[2] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [J].

Jaeger, Hans ;

Overton, Edgar ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Andrade-Villanueva, Jaime Federico ;

Mngqibisa, Rosie ;

Hermida, Antonio Ocampo ;

Thalme, Anders ;

Belonosova, Elena ;

Ajana, Faiza ;

Benn, Paul D. ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Espanol, Carlos Martin ;

Ford, Susan L. ;

Crauwels, Herta ;

Margolis, David A. ;

Talarico, Christine L. ;

Smith, Kimberly Y. ;

van Eygen, Veerle ;

Van Solingen-Ristea, Rodica ;

Vanveggel, Simon ;

Spreen, William R. .

LANCET HIV, 2021, 8 (11) :E679-E689

[3] Cabotegravir Plus Rilpivirine: First Approval [J].

Markham, A. .

DRUGS, 2020, 80 (09) :915-922

[4] Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients [J].

Mitsumoto-Kaseida, Fujiko ;

Murata, Masayuki ;

Takayama, Koji ;

Toyoda, Kazuhiro ;

Ogawa, Eiichi ;

Furusyo, Norihiro ;

Hayashi, Jun .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (01) :28-32

[5] Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan [J].

Naito, Toshio ;

Suzuki, Mai ;

Fukushima, Shinichi ;

Yuda, Mayumi ;

Fukui, Nobuyuki ;

Tsukamoto, Shotaro ;

Fujibayashi, Kazutoshi ;

Goto-Hirano, Keiko ;

Kuwatsuru, Ryohei .

HIV MEDICINE, 2022, 23 (05) :485-493

[6]

Orkin C, 2021, LANCET HIV, V8, pe185, DOI 10.1016/S2352-3018(20)30340-4

[7] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [J].

Overton, Edgar T. ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Jaeger, Hans ;

Orrell, Catherine ;

Nagimova, Firaya ;

Bredeek, Fritz ;

Deltoro, Miguel Garcia ;

Swindells, Susan ;

Andrade-Villanueva, Jaime Federico ;

Wong, Alexander ;

Khuong-Josses, Marie-Aude ;

Van Solingen-Ristea, Rodica ;

van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan ;

Talarico, Christine ;

Benn, Paul ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Chounta, Vasiliki ;

Cutrell, Amy ;

Patel, Parul ;

Shaefer, Mark ;

Margolis, David A. ;

Smith, Kimberly Y. ;

Vanveggel, Simon ;

Spreen, William .

LANCET, 2020, 396 (10267) :1994-2005

[8] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials [J].

Rizzardini, Giuliano ;

Overton, Edgar T. ;

Orkin, Chloe ;

Swindells, Susan ;

Arasteh, Keikawus ;

Gorgolas Hernandez-Mora, Miguel ;

Pokrovsky, Vadim ;

Girard, Pierre-Marie ;

Oka, Shinichi ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary J. ;

Baumgarten, Axel ;

Masia, Mar ;

Latiff, Gulam ;

Griffith, Sandy ;

Harrington, Conn M. ;

Hudson, Krischan J. ;

St Clair, Marty ;

Talarico, Christine L. ;

Patel, Parul ;

Cutrell, Amy ;

Van Eygen, Veerle ;

D'Amico, Ronald ;

Mrus, Joseph M. ;

Wu, Sterling ;

Ford, Susan L. ;

Chow, Ken ;

Roberts, Jeremy ;

Wills, Angela ;

Walters, Nicola ;

Vanveggel, Simon ;

Van Solingen-Ristea, Rodica ;

Crauwels, Herta ;

Smith, Kimberly Y. ;

Spreen, William R. ;

Margolis, David A. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) :498-506

← 1 →